HCW Biologics Inc
Company Profile
Business description
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
Contact
2929 N. Commerce Parkway
MiramarFL33025
USAT: +1 954 842-2024
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
35
Stocks News & Analysis
stocks
Chart of the Week: CGT reform strengthens the case for dividend investing
stocks
Finding ASX opportunities in lofty market conditions
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,122.70 | 62.80 | -0.68% |
| CAC 40 | 8,493.10 | 84.83 | 1.01% |
| DAX 40 | 25,528.77 | 68.29 | 0.27% |
| Dow JONES (US) | 51,594.14 | 1,153.18 | -2.19% |
| FTSE 100 | 10,946.37 | 37.96 | 0.35% |
| HKSE | 25,858.88 | 50.96 | 0.20% |
| NASDAQ | 24,442.94 | 433.97 | -1.74% |
| Nikkei 225 | 61,867.43 | 433.24 | 0.71% |
| NZX 50 Index | 13,762.78 | 213.89 | -1.53% |
| S&P 500 | 7,316.15 | 112.63 | -1.52% |
| S&P/ASX 200 | 8,967.70 | 57.10 | -0.63% |
| SSE Composite Index | 3,804.69 | 23.78 | -0.62% |